Scheiermann N, Kuwert E K
Dtsch Med Wochenschr. 1977 Sep 30;102(39):1370-3. doi: 10.1055/s-0028-1106728.
Possible side effects to two commercial influenza vaccines (Alorbat and Begrivac S) were investigated in 893 adults (18-60 years). Both vaccines, administered by jet injections, were similarly tolerated. About 90% of vaccinated subjects had neither subjective nor objective reactions. Swelling or pain at the site of injection was reported by 11.5% of those vaccinated by Alorbat, 4.5% complained of not feeling well but only 1.1% had verifiable disorders. Local reactions occurred in 12.4% of those receiving Begrivac S, with 7.7% systemic reactions of which 1.1% were verifiable. Those re-vaccinated had a similar incidence of side reactions to those with primary vaccinations. Reactions which did occur were obviously due to the vaccination method. One person had urticaria and oedema, possibly due to reaction to foreign protein; this would suggest that the degree of purity of the vaccine should be checked by the manufacturers.
在893名18至60岁的成年人中,对两种市售流感疫苗(Alorbat和Begrivac S)的可能副作用进行了调查。两种疫苗均通过喷射注射给药,耐受性相似。约90%的接种者既无主观反应也无客观反应。接种Alorbat的人中,11.5%报告注射部位出现肿胀或疼痛,4.5%主诉身体不适,但只有1.1%有可证实的病症。接种Begrivac S的人中有12.4%出现局部反应,7.7%出现全身反应,其中1.1%有可证实的反应。再次接种者的副作用发生率与初次接种者相似。确实出现的反应显然是由于接种方法所致。一人出现荨麻疹和水肿,可能是对外源蛋白的反应;这表明制造商应检查疫苗的纯度。